UK's MHRA approves single-dose 7.2mg semaglutide (Wegovy) pen for adults with obesity
Clinicians can immediately prescribe single‑dose 7.2mg Wegovy for adults with BMI ≥30
Change
UK's MHRA approved on 14 April 2026 a single-dose 7.2mg semaglutide (Wegovy) pen to treat adult patients with obesity defined as a Body Mass Index of 30kg/m² or higher.
Why it matters
Dispensing and prescribing workflows must be changed to accommodate a single‑injection maximum dose rather than multiple smaller pens. Pharmacy procurement and supply‑chain teams need to adapt stock formats and handling protocols to avoid administration errors or supply interruptions.
Implications
- — Primary care prescribers (general practitioners and nurse prescribers treating adult obesity) — must immediately update prescribing templates and patient counselling to include the single‑dose 7.2mg option for eligible patients (BMI ≥30kg/m²) — otherwise patients risk incorrect dosing or inappropriate treatment choices.
- — Community pharmacy dispensing teams — must review and integrate the Summary of Product Characteristics and Patient Information leaflets when published by April 21, 2026 — failure to do so risks dispensing errors and incorrect administration advice to patients.
Unlock the decision layer.
Know what's at risk and what to do next.
- Implications: What this forces you to change — operations, exposure, or compliance.
- Who is affected: Which roles, contracts, and obligations are exposed.
- What to watch: Binding deadlines and enforcement dates.
- Real-time alerts: Delivered the moment a binding change is published.
- Ask AI: Ask what this means for your specific role.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer